Neuland Labs: FY26 results, ₹34 dividend, capacity expansion, new director
Neuland Laboratories · Pharmaceuticals & Biotechnology
Key highlights
- Consolidated FY26 revenue from operations ₹2,02,298.54 lakhs; profit for the year ₹36,399.84 lakhs against ₹26,010.81 lakhs for the year ended 31.03.2025
- Final dividend ₹34/- per equity share of ₹10 recommended; record date July 24, 2026; 42nd AGM on August 4, 2026
- Unit 1 capacity addition of 120.5 KL in 12 to 18 months, investment ₹143.4 crores (incl GST), funded by internal accruals and borrowings
Why it's rated major development: the year-on-year change is 665% (50% or more)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Board Meeting Outcome for Board Meeting Outcome For Audited Financial Results And Recommendation Of Final Dividend For Financial Year 2025-26
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Neuland Laboratories
- Financial resultsMajor developmentNeuland Q1 net profit up to ₹14,767.31 lakhs; Gland guarantee, Unit 1 capex approved
- Capex / expansionMajor developmentNeuland Laboratories reports Q1 FY 2027 results and announces Gland Pharma partnership
- Capex / expansionMajor developmentNeuland Q1 profit 14,767.31 lakhs vs 1,390.00 lakhs; Gland Pharma sterile API tie-up
- Capex / expansionNotableNeuland Laboratories Limited announces commercial production start of expanded capacities
- Dividend / buyback / bonusMajor developmentNeuland Laboratories approves FY26 audited results, ₹34 dividend, director appointment
Other financial results filings this fortnight
- Siddhika Coatings Limited approves joint venture and announces H1 FY 2026 financials
- Financial resultsBrooks LaboratoriesBrooks Laboratories Limited announces Q2 and H1 FY2026 unaudited financial results
- Financial resultsBrooks LaboratoriesBrooks Laboratories Limited announces Q2 and H1 FY2027 financial results and divestment
- NHC Foods reports Sept 2026 quarter results, 99.98% firm stake, two appointments
- Spectrum Electrical Industries Ltd approves Q2 & H1 results for period ended September 30, 2026
- Dev Labtech Venture reports unaudited half-year results to 30 Sept 2026
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.